Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.

J Exp Clin Cancer Res · 2014 · PMC4192339 · PMID 25272957

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Finally, AREG-/EREG-/PTEN+ patients showed a trend to live longer under combined treatment combination.

also in 53,322 other papers

a clear trendno p-value reported

However, AREG-/EREG-/PTEN + patients showed a clear trend to profit from the addition of irinotean to the adjuvant regime (Figure 7 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.